LABFF
Laboratorios Farmaceuticos Rovi, S.A.
Price Chart
Latest Quote
$90.61
+0.00 (+0.00%)
Current Price
| Previous Close | $90.61 |
| Open | $90.61 |
| Day High | $90.61 |
| Day Low | $90.61 |
| Volume | 100 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 51.15M |
| Total Debt | $130.15M |
| Cash Equivalents | $110.76M |
| Revenue | $842.81M |
| Net Income | $149.91M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.63B |
| P/E Ratio | 28.95 |
| EPS (TTM) | $3.13 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.40B |
| Sales | $842.81M |
| Income | $149.91M |
| Book/sh | $15.10 |
| Cash/sh | $1.90 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 1.77 |
| Current Ratio | 3.65 |
| Debt/Eq | 16.66 |
| EPS Growth TTM | -47.60% |
Returns & Margins
| ROA | 11.50% |
| ROE | 20.48% |
| Gross Margin | 63.97% |
| Operating Margin | 6.48% |
| Profit Margin | 17.79% |
Ownership
| Insider Ownership | 68.20% |
| Institutional Ownership | 19.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 6.25 |
| P/B | 6.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $90.61 |
| SMA50 | $90.61 |
| SMA200 | $90.61 |
| RSI | nan |
| Shares Float | 16.21M |
| Volatility | 0.22 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +0.00% |
| YTD | +0.00% |
| Year | +1.04% |
| 3 Years | +86.09% |
| 5 Years | -104.57% |
| 10 Years | -105.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $90.61 | 0 |
| 2026-06-23 | $90.61 | 0 |
| 2026-06-22 | $90.61 | 0 |
| 2026-06-18 | $90.61 | 0 |
| 2026-06-17 | $90.61 | 0 |
| 2026-06-16 | $90.61 | 0 |
| 2026-06-15 | $90.61 | 0 |
| 2026-06-12 | $90.61 | 0 |
| 2026-06-11 | $90.61 | 0 |
| 2026-06-10 | $90.61 | 0 |
| 2026-06-09 | $90.61 | 0 |
| 2026-06-08 | $90.61 | 0 |
| 2026-06-05 | $90.61 | 0 |
| 2026-06-04 | $90.61 | 0 |
| 2026-06-03 | $90.61 | 0 |
| 2026-06-02 | $90.61 | 0 |
| 2026-06-01 | $90.61 | 0 |
| 2026-05-29 | $90.61 | 0 |
| 2026-05-28 | $90.61 | 0 |
| 2026-05-27 | $90.61 | 0 |
| 2026-05-26 | $90.61 | 0 |
About Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de AlarcÃŗn, Spain. Laboratorios FarmaceÃēticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
đ° Latest News
Global Market Highlights 3 Stocks That May Be Trading Below Fair Value Estimates
Simply Wall St. âĸ 2026-05-26T09:37:59Z
Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q1 2026 Earnings Call Highlights: Navigating ...
GuruFocus.com âĸ 2026-05-07T22:31:24ZLaboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth ...
GuruFocus.com âĸ 2026-02-28T01:00:30Z3 European Stocks Estimated To Be Trading At Discounts Of Up To 46%
Simply Wall St. âĸ 2026-02-11T05:38:18Z
Uncovering 3 European Stocks That May Be Priced Below Intrinsic Value Estimates
Simply Wall St. âĸ 2026-01-13T05:38:10Z
December 2025 European Stocks That May Be Trading Below Fair Value
Simply Wall St. âĸ 2025-12-15T05:37:57Z
Global Value Stocks Priced Below Estimated Worth In November 2025
Simply Wall St. âĸ 2025-11-14T09:37:59Z
European Market Picks: 3 Stocks That May Be Trading Below Their Estimated Value
Simply Wall St. âĸ 2025-10-16T05:37:50Z
September 2025's European Stocks Estimated To Be Trading Below Fair Value
Simply Wall St. âĸ 2025-09-11T10:38:05Z
3 European Stocks Estimated To Be Trading At Discounts Up To 49.1%
Simply Wall St. âĸ 2025-08-13T10:37:54Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $285,403,000 | $337,224,000 | $298,085,000 | $263,855,000 |
| Cost Of Revenue | $285,403,000 | $337,224,000 | $298,085,000 | $263,855,000 |
| Total Revenue | $763,749,000 | $829,509,000 | $817,698,000 | $648,677,000 |
| Operating Revenue | $763,749,000 | $829,509,000 | $817,698,000 | $648,677,000 |
| Expenses | ||||
| Interest Expense | $1,988,000 | $667,000 | $606,000 | $669,000 |
| Total Expenses | $584,204,000 | $609,255,000 | $561,848,000 | $467,190,000 |
| Rent Expense Supplemental | $860,000 | $2,462,000 | $3,470,000 | $839,000 |
| Net Non Operating Interest Income Expense | $-2,091,000 | $556,000 | $921,000 | $-837,000 |
| Total Other Finance Cost | $129,000 | $-1,216,000 | $-1,521,000 | $236,000 |
| Interest Expense Non Operating | $1,988,000 | $667,000 | $606,000 | $669,000 |
| Operating Expense | $298,801,000 | $272,031,000 | $263,763,000 | $203,335,000 |
| Other Operating Expenses | $95,682,000 | $85,235,000 | $100,237,000 | $79,950,000 |
| Selling And Marketing Expense | $21,737,000 | $21,754,000 | $19,993,000 | $12,713,000 |
| General And Administrative Expense | $17,688,000 | $16,223,000 | $12,782,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $136,881,000 | $170,335,000 | $199,669,000 | $153,077,000 |
| Net Interest Income | $-2,091,000 | $556,000 | $921,000 | $-837,000 |
| Interest Income | $26,000 | $7,000 | $6,000 | $68,000 |
| Normalized Income | $136,818,630 | $170,482,643 | $198,261,878 | $151,418,840 |
| Net Income From Continuing And Discontinued Operation | $136,881,000 | $170,335,000 | $199,669,000 | $153,077,000 |
| Total Operating Income As Reported | $179,545,000 | $220,254,000 | $255,848,000 | $181,392,000 |
| Net Income Common Stockholders | $136,881,000 | $170,335,000 | $199,669,000 | $153,077,000 |
| Net Income | $136,881,000 | $170,335,000 | $199,669,000 | $153,077,000 |
| Net Income Including Noncontrolling Interests | $136,876,000 | $170,299,000 | $199,665,000 | $153,077,000 |
| Net Income Continuous Operations | $136,876,000 | $170,299,000 | $199,665,000 | $153,077,000 |
| Pretax Income | $177,690,000 | $220,408,000 | $257,967,000 | $182,628,000 |
| Special Income Charges | $81,000 | $0 | $-2,000 | $-95,000 |
| Interest Income Non Operating | $26,000 | $7,000 | $6,000 | $68,000 |
| Operating Income | $179,545,000 | $220,254,000 | $255,850,000 | $181,487,000 |
| Depreciation And Amortization In Income Statement | $28,015,000 | $24,331,000 | $22,871,000 | $21,364,000 |
| Depreciation Income Statement | $28,015,000 | $24,331,000 | $22,871,000 | $21,364,000 |
| Gross Profit | $478,346,000 | $492,285,000 | $519,613,000 | $384,822,000 |
| Per Share | ||||
| Diluted EPS | $2.68 | $3.29 | $3.73 | $2.76 |
| Basic EPS | $2.68 | $3.29 | $3.73 | $2.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $18,630 | $-43,357 | $410,878 | $315,840 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $207,612,000 | $245,597,000 | $279,626,000 | $202,687,000 |
| Total Unusual Items | $81,000 | $-191,000 | $1,818,000 | $1,974,000 |
| Total Unusual Items Excluding Goodwill | $81,000 | $-191,000 | $1,818,000 | $1,974,000 |
| Reconciled Depreciation | $28,015,000 | $24,331,000 | $22,871,000 | $21,364,000 |
| EBITDA (Bullshit earnings) | $207,693,000 | $245,406,000 | $281,444,000 | $204,661,000 |
| EBIT | $179,678,000 | $221,075,000 | $258,573,000 | $183,297,000 |
| Diluted Average Shares | $51,149,498 | $51,820,146 | $53,466,000 | $55,404,000 |
| Basic Average Shares | $51,149,498 | $51,820,146 | $53,466,000 | $55,404,000 |
| Diluted NI Availto Com Stockholders | $136,881,000 | $170,335,000 | $199,669,000 | $153,077,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $5,000 | $36,000 | $4,000 | $0 |
| Tax Provision | $40,814,000 | $50,109,000 | $58,302,000 | $29,551,000 |
| Write Off | $-81,000 | $219,000 | $2,000 | $95,000 |
| Selling General And Administration | $39,425,000 | $37,977,000 | $32,775,000 | $12,713,000 |
| Rent And Landing Fees | $860,000 | $2,462,000 | $3,470,000 | $839,000 |
| Impairment Of Capital Assets | - | $0 | $2,000 | $95,000 |
| Amortization | - | - | - | $21,364,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $538,078,000 | $505,485,000 | $484,268,000 | $432,418,000 |
| Total Assets | $832,022,000 | $799,884,000 | $878,703,000 | $732,676,000 |
| Total Non Current Assets | $342,416,000 | $290,553,000 | $255,630,000 | $226,314,000 |
| Other Non Current Assets | $65,000 | - | - | - |
| Non Current Deferred Taxes Assets | $2,263,000 | $2,343,000 | $2,078,000 | $3,850,000 |
| Investmentin Financial Assets | $0 | $24,000 | $9,000 | $72,000 |
| Goodwill And Other Intangible Assets | $33,950,000 | $33,902,000 | $35,744,000 | $38,558,000 |
| Other Intangible Assets | $33,950,000 | $33,902,000 | $35,744,000 | $38,558,000 |
| Current Assets | $489,606,000 | $509,331,000 | $623,073,000 | $506,362,000 |
| Other Current Assets | $2,687,000 | - | - | - |
| Prepaid Assets | $2,687,000 | $2,727,000 | $2,025,000 | $1,791,000 |
| Inventory | $329,954,000 | $337,968,000 | $311,944,000 | $245,473,000 |
| Other Receivables | $14,644,000 | - | - | - |
| Taxes Receivable | $81,000 | $0 | $4,148,000 | $9,891,000 |
| Accounts Receivable | $129,471,000 | $143,314,000 | $180,011,000 | $150,172,000 |
| Cash Cash Equivalents And Short Term Investments | $27,413,000 | $25,322,000 | $124,945,000 | $99,035,000 |
| Cash And Cash Equivalents | $27,186,000 | $25,322,000 | $124,945,000 | $99,035,000 |
| Cash Equivalents | $6,006,000 | $0 | $44,425,000 | $0 |
| Cash Financial | $21,180,000 | $25,322,000 | $80,520,000 | $99,035,000 |
| Debt | ||||
| Net Debt | $71,159,000 | $21,313,000 | - | - |
| Total Debt | $114,410,000 | $65,427,000 | $72,138,000 | $73,145,000 |
| Long Term Debt And Capital Lease Obligation | $90,719,000 | $52,242,000 | $59,441,000 | $66,745,000 |
| Long Term Debt | $80,503,000 | $38,575,000 | $46,044,000 | $52,523,000 |
| Current Debt And Capital Lease Obligation | $23,691,000 | $13,185,000 | $12,697,000 | $6,400,000 |
| Current Debt | $17,842,000 | $8,060,000 | $8,238,000 | $2,959,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $250,482,000 | $256,390,000 | $357,324,000 | $261,700,000 |
| Total Non Current Liabilities Net Minority Interest | $93,831,000 | $56,547,000 | $63,437,000 | $71,312,000 |
| Other Non Current Liabilities | $2,746,000 | - | - | - |
| Non Current Deferred Taxes Liabilities | $366,000 | $1,515,000 | $677,000 | $776,000 |
| Current Liabilities | $156,651,000 | $199,843,000 | $293,887,000 | $190,388,000 |
| Other Current Liabilities | $5,248,000 | - | - | - |
| Payables | $120,191,000 | $139,552,000 | $159,298,000 | $120,388,000 |
| Other Payable | $30,956,000 | $26,704,000 | $35,397,000 | $22,300,000 |
| Total Tax Payable | $2,384,000 | $5,255,000 | $0 | $681,000 |
| Accounts Payable | $86,851,000 | $107,593,000 | $123,901,000 | $97,407,000 |
| Equity | ||||
| Common Stock Equity | $572,028,000 | $539,387,000 | $520,012,000 | $470,976,000 |
| Total Equity Gross Minority Interest | $581,540,000 | $543,494,000 | $521,379,000 | $470,976,000 |
| Stockholders Equity | $572,028,000 | $539,387,000 | $520,012,000 | $470,976,000 |
| Retained Earnings | $486,213,000 | $555,534,000 | $456,031,000 | $445,426,000 |
| Long Term Equity Investment | $19,516,000 | $567,000 | $2,193,000 | $1,994,000 |
| Other | ||||
| Treasury Shares Number | $86,264 | $2,196,011 | $1,644,144 | $1,253,266 |
| Ordinary Shares Number | $51,149,498 | $51,820,146 | $52,372,013 | $54,815,699 |
| Share Issued | $51,235,762 | $54,016,157 | $54,016,157 | $56,068,965 |
| Tangible Book Value | $538,078,000 | $505,485,000 | $484,268,000 | $432,418,000 |
| Invested Capital | $670,373,000 | $586,022,000 | $574,294,000 | $526,458,000 |
| Working Capital | $332,955,000 | $309,488,000 | $329,186,000 | $315,974,000 |
| Capital Lease Obligations | $16,065,000 | $18,792,000 | $17,856,000 | $17,663,000 |
| Total Capitalization | $652,531,000 | $577,962,000 | $566,056,000 | $523,499,000 |
| Minority Interest | $9,512,000 | $4,107,000 | $1,367,000 | $0 |
| Treasury Stock | $5,545,000 | $107,676,000 | $27,561,000 | $66,121,000 |
| Additional Paid In Capital | $87,636,000 | $87,636,000 | $87,636,000 | $87,636,000 |
| Capital Stock | $3,074,000 | $3,241,000 | $3,241,000 | $3,364,000 |
| Common Stock | $3,074,000 | $3,241,000 | $3,241,000 | $3,364,000 |
| Non Current Deferred Revenue | $2,746,000 | $2,790,000 | $3,319,000 | $3,791,000 |
| Long Term Capital Lease Obligation | $10,216,000 | $13,667,000 | $13,397,000 | $14,222,000 |
| Current Capital Lease Obligation | $5,849,000 | $5,125,000 | $4,459,000 | $3,441,000 |
| Investmentsin Joint Venturesat Cost | $19,516,000 | $567,000 | $2,193,000 | $1,994,000 |
| Net PPE | $286,622,000 | $253,652,000 | $215,541,000 | $181,775,000 |
| Accumulated Depreciation | $-245,216,000 | $-227,033,000 | $-206,336,000 | $-187,426,000 |
| Gross PPE | $531,838,000 | $480,685,000 | $421,877,000 | $369,201,000 |
| Construction In Progress | $11,009,000 | $8,469,000 | $40,174,000 | $28,055,000 |
| Other Properties | $41,847,000 | $59,442,000 | $52,219,000 | $46,899,000 |
| Machinery Furniture Equipment | $404,185,000 | $352,129,000 | $284,365,000 | $256,997,000 |
| Properties | $74,797,000 | $60,645,000 | $45,119,000 | $37,250,000 |
| Finished Goods | $95,352,000 | $88,095,000 | $74,192,000 | $70,086,000 |
| Work In Process | $128,415,000 | $80,505,000 | $78,723,000 | $50,447,000 |
| Raw Materials | $106,187,000 | $169,368,000 | $159,029,000 | $124,940,000 |
| Other Short Term Investments | $227,000 | - | - | - |
| Available For Sale Securities | - | $24,000 | $9,000 | $72,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $76,059,000 | $58,060,000 | $186,214,000 | $108,501,000 |
| Operating Activities | ||||
| Operating Cash Flow | $138,278,000 | $113,247,000 | $237,602,000 | $149,441,000 |
| Investing Activities | ||||
| Capital Expenditure | $-62,219,000 | $-55,187,000 | $-51,388,000 | $-40,940,000 |
| Investing Cash Flow | $-81,058,000 | $-52,028,000 | $-57,154,000 | $-40,839,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-89,708,000 | $-133,900,000 | $-177,008,000 | $-78,785,000 |
| Issuance Of Capital Stock | $41,921,000 | $52,639,000 | $77,766,000 | $42,328,000 |
| Financing Cash Flow | $-55,356,000 | $-160,842,000 | $-154,538,000 | $-62,729,000 |
| Net Other Financing Charges | $5,410,000 | $2,776,000 | $1,371,000 | - |
| Cash Dividends Paid | $-56,451,000 | $-69,049,000 | $-51,007,000 | $-21,132,000 |
| Common Stock Dividend Paid | $-56,451,000 | $-69,049,000 | $-51,007,000 | $-21,132,000 |
| Net Common Stock Issuance | $-47,787,000 | $-81,261,000 | $-99,242,000 | $-36,457,000 |
| Common Stock Issuance | $41,921,000 | $52,639,000 | $77,766,000 | $42,328,000 |
| Other | ||||
| Repayment Of Debt | $-51,711,000 | $-13,654,000 | $-6,768,000 | $-6,192,000 |
| Issuance Of Debt | $96,952,000 | $734,000 | $1,399,000 | $1,340,000 |
| End Cash Position | $27,186,000 | $25,322,000 | $124,945,000 | $99,035,000 |
| Beginning Cash Position | $25,322,000 | $124,945,000 | $99,035,000 | $53,162,000 |
| Changes In Cash | $1,864,000 | $-99,623,000 | $25,910,000 | $45,873,000 |
| Interest Paid Cff | $-1,769,000 | $-388,000 | $-291,000 | $-288,000 |
| Common Stock Payments | $-89,708,000 | $-133,900,000 | $-177,008,000 | $-78,785,000 |
| Net Issuance Payments Of Debt | $45,241,000 | $-12,920,000 | $-5,369,000 | $-4,852,000 |
| Net Long Term Debt Issuance | $45,241,000 | $-12,920,000 | $-5,369,000 | $-4,852,000 |
| Long Term Debt Payments | $-51,711,000 | $-13,654,000 | $-6,768,000 | $-6,192,000 |
| Long Term Debt Issuance | $96,952,000 | $734,000 | $1,399,000 | $1,340,000 |
| Interest Received Cfi | $134,000 | $1,489,000 | $6,000 | $68,000 |
| Net Investment Purchase And Sale | $80,000 | $88,000 | $-5,850,000 | $0 |
| Sale Of Investment | $80,000 | $88,000 | $20,000 | $0 |
| Net Business Purchase And Sale | $-19,090,000 | $1,200,000 | $0 | - |
| Sale Of Business | $0 | $1,800,000 | $0 | - |
| Purchase Of Business | $-19,090,000 | $-600,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-3,100,000 | $-1,393,000 | $-669,000 | $-722,000 |
| Purchase Of Intangibles | $-3,100,000 | $-1,393,000 | $-669,000 | $-722,000 |
| Net PPE Purchase And Sale | $-59,082,000 | $-53,412,000 | $-50,641,000 | $-40,185,000 |
| Sale Of PPE | $37,000 | $382,000 | $78,000 | $33,000 |
| Purchase Of PPE | $-59,119,000 | $-53,794,000 | $-50,719,000 | $-40,218,000 |
| Taxes Refund Paid | $-44,230,000 | $-40,856,000 | $-43,889,000 | $-23,861,000 |
| Change In Working Capital | $8,960,000 | $-34,448,000 | $-56,973,000 | $-64,034,000 |
| Change In Other Current Assets | $40,000 | $-702,000 | $-234,000 | $-1,778,000 |
| Change In Payable | $-16,361,000 | $-23,923,000 | $41,672,000 | $35,358,000 |
| Change In Inventory | $11,871,000 | $-29,294,000 | $-71,591,000 | $-23,427,000 |
| Change In Receivables | $13,410,000 | $19,471,000 | $-26,820,000 | $-74,187,000 |
| Other Non Cash Items | $885,000 | $-1,675,000 | $-3,825,000 | $-5,636,000 |
| Depreciation And Amortization | $28,015,000 | $24,331,000 | $22,871,000 | $21,364,000 |
| Amortization Cash Flow | $3,042,000 | $3,268,000 | $3,481,000 | - |
| Depreciation | $24,973,000 | $21,063,000 | $19,390,000 | $21,364,000 |
| Gain Loss On Investment Securities | $-81,000 | $191,000 | $-1,820,000 | $-2,069,000 |
| Net Foreign Currency Exchange Gain Loss | $-296,000 | $86,000 | $821,000 | $0 |
| Gain Loss On Sale Of PPE | $4,394,000 | $0 | - | - |
| Net Income From Continuing Operations | $177,690,000 | $220,408,000 | $257,967,000 | $182,628,000 |
| Purchase Of Investment | - | $0 | $-5,870,000 | $0 |
| Other Cash Adjustment Outside Changein Cash | - | - | $-1,000 | - |
| Interest Paid Cfo | - | - | $0 | $-4,000 |
| Stock Based Compensation | - | - | $0 | $1,403,000 |
| Provisionand Write Offof Assets | - | - | $5,160,000 | $4,885,000 |
| Change In Prepaid Assets | - | - | - | $-1,778,000 |
Fetched: 2026-02-02